INCHEON, South Korea–(BUSINESS WIRE)–Celltrion today announced that the European Commission (EC) has approved the use of SteQeyma^{\u00ae <\/sup>(CT-P43), an ustekinumab biosimilar referencing Stelara\u00ae<\/sup>, for the treatment of multiple chronic inflammatory diseases. SteQeyma is approved as a biologic therapy in gastroenterology, dermatology and rheumatology indications.1<\/sup> Stelara was the first biologic therapy for Crohn\u2019s disease to target interleukin (IL)-12 and IL-23 cytokines, known to play a key role in inflammatory and immune responses.2<\/sup><\/p>\n}

<\/a>
<\/a><\/p>\n

\nThe decision from the EC follows a positive opinion recommending SteQeyma from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in June 2024.^{3<\/sup><\/p>\n}

\nThe EC approval of SteQeyma was based on the totality of evidence, including the results from a Phase III study in adults with moderate to severe plaque psoriasis, in which the primary endpoint was the rate of change in the Psoriasis Area and Severity Index (PASI) for skin symptoms. The clinical results demonstrated that SteQeyma is highly similar to its reference product, Stelara, and has no clinically meaningful differences in terms of efficacy and safety.^{4,5<\/sup><\/p>\n}

\n\u201cThe EC approval of SteQeyma brings an important new therapeutic option to patients and we\u2019re excited to launch this innovative therapy, with a proven track record in Crohn\u2019s and other immune diseases,\u201d said Taehun Ha, Senior Vice President and Head of Europe Division at Celltrion. \u201cThis approval, alongside those of Remsima SC and Yuflyma, marks a key milestone in our strategy to strengthen Celltrion\u2019s immunology offering, and with the recent approval of Omlyclo in May, we are looking forward to expanding our portfolio into the dermatology sector. We believe the approval demonstrates our unwavering commitment to expanding patient access to affordable, high-quality biologic medicines.\u201d<\/p>\n

\nSteQeyma is Celltrion\u2019s seventh biosimilar approved for use in the European Union (EU). Alongside Remsima^{\u00ae<\/sup> SC, a subcutaneous formulation of infliximab approved in the EU, SteQeyma joins Celltrion\u2019s distinguished portfolio that includes Remsima\u00ae <\/sup>(biosimilar infliximab), Truxima\u00ae<\/sup> (biosimilar rituximab), Herzuma\u00ae<\/sup> (biosimilar trastuzumab), Yuflyma\u00ae <\/sup>(biosimilar adalimumab), Vegzelma\u00ae<\/sup> (biosimilar bevacizumab) and Omlyclo\u00ae <\/sup>(biosimilar omalizumab).<\/p>\n}

\nAbout SteQeyma^{\u00ae<\/sup> (CT-P43, biosimilar ustekinumab)<\/b>1<\/sup><\/p>\n}

\nSteQeyma^{\u00ae<\/sup>, formerly known as CT-P43, is a human IL-12 and IL-23 antagonist indicated for multiple immune-mediated diseases. SteQeyma is available in both subcutaneous and intravenous formulations. The subcutaneous injection comes in two strengths: 45mg\/0.5 mL or 90mg\/1 mL solution in a single-dose, prefilled syringe. The intravenous infusion is provided as a 130mg\/26 mL (5mg\/mL) solution in a single-dose vial.<\/p>\n}

\nAbout Celltrion<\/b><\/p>\n

\nCelltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. The company\u2019s solutions include world-class monoclonal antibody biosimilars such as Remsima^{\u00ae<\/sup>, Truxima\u00ae<\/sup> and Herzuma\u00ae<\/sup>, providing broader patient access globally. Celltrion has also received U.S. FDA and EC approval for Vegzelma\u00ae<\/sup>, Yuflyma\u00ae <\/sup>and Omlyclo\u00ae<\/sup>, FDA approval for Zymfentra\u00ae<\/sup>, and EC approval for Remsima\u00ae <\/sup>SC. To learn more, please visit} www.celltrion.com\/en-us<\/a>.<\/p>\n

\nFORWARD-LOOKING STATEMENT<\/b><\/p>\n

\nCertain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.<\/p>\n

\nThese statements may be identified by words such as \u201cprepares\u201d, \u201chopes to\u201d, \u201cupcoming\u201d, \u201dplans to\u201d, \u201caims to\u201d, \u201cto be launched\u201d, \u201cis preparing, \u201conce gained\u201d, \u201ccould\u201d, \u201cwith the aim of\u201d, \u201cmay\u201d, \u201conce identified\u201d, \u201cwill\u201d, \u201cworking towards\u201d, \u201cis due\u201d, \u201cbecome available\u201d, \u201chas potential to\u201d, the negative of these words or such other variations thereon or comparable terminology.<\/p>\n

\nIn addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries’ management, of which many are beyond its control.<\/p>\n

\nForward-looking statements are provided to allow potential investors the opportunity to understand management\u2019s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.<\/p>\n

\nSuch forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.<\/p>\n

\nAlthough forward-looking statements contained in this presentation are based upon what management of Celltrion Inc. and its subsidiaries believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management\u2019s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.<\/p>\n

\nTrademark<\/b><\/span><\/p>\n

\nStelara^{\u00ae<\/sup> is a registered trademark of Johnson & Johnson.
\n
SteQeyma\u00ae <\/sup>is a registered trademark of Celltrion, Inc., used under license.<\/p>\n}

\nReferences<\/b><\/span><\/p>\n

\n^{1<\/sup> European Medicines Agency Summary of Product Characteristics (SmPC), SteQeyma.
\n
2<\/sup> European Medicines Agency. Summary of Product Characteristics (SmPC), STELARA Available at:} https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stelara-epar-product-information_en.pdf<\/a>. [Last accessed August 2024].
\n
^{3<\/sup> European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024. Available at:} https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024<\/a>. [Last accessed August 2024].
\n
^{4<\/sup> Papp KA et al.,<\/i> Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III study. BioDrugs. 2023; Available at:} https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00630-5<\/a>. [Last accessed August 2024].
\n
^{5<\/sup> Papp K et al., <\/i>Efficacy and Safety after Switch from Reference Ustekinumab to Ustekinumab Biosimilar (CT-P43) in comparison with the Maintenance Group (CT-P43 or Reference Ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis: 1-Year Result. [EADV 2023, Abstract #4035]. Available at:} https:\/\/eadv.org\/wp-content\/uploads\/scientific-abstracts\/EADV-congress-2023\/Biologics-immunotherapy-targeted-therapy.pdf<\/a>. [Last accessed August 2024].<\/p>\n

Contacts<\/b> <\/p>\n

\nDonna Gandhi
\n
dgandhi@hanovercomms.com<\/a>
+44 (0) 203 817 6591<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SteQeyma\u00ae (CT-P43) is approved as a biologic therapy in gastroenterology, dermatology and rheumatology indications1 The European Commission (EC) approval is based on the totality of evidence including the results from …<\/p>\n","protected":false},"author":162,"featured_media":264028,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","_glsr_average":0,"_glsr_ranking":0,"_glsr_reviews":0,"footnotes":""},"categories":[340],"tags":[],"class_list":["post-264027","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-businesswire"],"_links":{"self":[{"href":"https:\/\/aijourn.com\/wp-json\/wp\/v2\/posts\/264027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aijourn.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/aijourn.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/aijourn.com\/wp-json\/wp\/v2\/users\/162"}],"replies":[{"embeddable":true,"href":"https:\/\/aijourn.com\/wp-json\/wp\/v2\/comments?post=264027"}],"version-history":[{"count":0,"href":"https:\/\/aijourn.com\/wp-json\/wp\/v2\/posts\/264027\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/aijourn.com\/wp-json\/wp\/v2\/media\/264028"}],"wp:attachment":[{"href":"https:\/\/aijourn.com\/wp-json\/wp\/v2\/media?parent=264027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/aijourn.com\/wp-json\/wp\/v2\/categories?post=264027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/aijourn.com\/wp-json\/wp\/v2\/tags?post=264027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}